SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presented at ASCO 2024
GlobeNewswire
· An additional 19 patients have been enrolled since January 2024 bringing the total to 37 of whom 25 were evaluable for..